Rezolute

Name: Rezolute
Address: 275 Shoreline Drive, Ste. 500, Redwood City, CA, 94065, US
Telephone: +16502064507
Price range: $$

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism

05/29/2026

Stories from families living with drive us forward. We’re inspired by their courage, and we’re dedicated to developing treatment options that will give them greater control over their lives.

Congenital hyperinsulinism (cHI) is the most common cause of recurrent and persistent in children. It can lead to progressive and irreversible damage over time, including serious and devastating neurological damage, seizures, neuro-developmental problems, feeding difficulties, and a profound impact on the quality of life for the patient and their family.

We’re working toward creating a different world - one where patients and caregivers no longer live in fear of unpredictable hypoglycemic lows.

Learn more: https://bit.ly/3OmZq0Z

05/20/2026

Today we celebrate , a time to honor the families and professionals who drive critical research forward.

❤️ Thank you to all the study participants who make medical advancement possible

❤️ Thank you to the clinical research professionals who ensure trials move forward safely and effectively

❤️ Thank you to the clinicians who guide participants through their treatment journey and advocate for better options

Learn more about our clinical trials here: https://bit.ly/42LzGj6

05/18/2026

We're excited to participate in the H.C. Wainwright Investor Conference in New York this week.

If you’re attending, we look forward to connecting to share updates on the exciting milestones ahead for our two late-stage programs.

05/14/2026

Navigating (HI) comes with challenges no one should face alone—that’s why we’re here to support and stay connected. Be sure to sign up for 𝘛𝘩𝘦 𝘙𝘦𝘻𝘰𝘭𝘶𝘵𝘪𝘰𝘯 and look out for our May edition.

𝘛𝘩𝘦 𝘙𝘦𝘻𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘙𝘦𝘱𝘰𝘳𝘵 brings awareness, resources, and support to those impacted by frequent and severe hypoglycemia related to HI.

Subscribe here: https://bit.ly/4iadvda

05/13/2026

We’re looking forward to the Neuroendocrine Cancer Foundation’s Patient Conference this Saturday, where people living with and their caregivers will meet with leading experts from Emory University, the University of Alabama at Birmingham, and Vanderbilt University.

This free, one-day event in Atlanta provides an opportunity for families navigating tumor to connect with other patients, hear the latest insights in neuroendocrine cancer care, and engage directly with specialists.

Learn more: https://bit.ly/4nq0G15

05/12/2026

Today we provided financial results and a business update for fiscal Q3 2026.

Learn more about our progress advancing care for patients and families living with congenital and tumor .

Read the full release: https://bit.ly/4uBRmJQ

05/11/2026

In May, we recognize by honoring the dedicated researchers and clinicians advancing care. We're grateful for their vital work, and we’re proud to contribute through our efforts to develop a safe and effective therapy for patients with tumor .

Visit the American Association for Cancer Research to learn how you can support: https://bit.ly/4uGf47C

05/07/2026

This week, Congenital Hyperinsulinism International is gathering families, clinicians, researchers, and advocacy leaders to exchange insights about caring for and living with congenital (cHI).

We’re proud to sponsor this special event that helps strengthen the vibrant community as we work toward better treatment options for patients.

05/06/2026

To the advancing care around the world: thank you for your commitment, advocacy, and heart. You make a profound difference in the lives of the families you serve.

05/01/2026

Today at the Pediatric Endocrine Society (PES) Annual Meeting, Principal Investigator Diva De León-Crutchlow presented results from the Phase 3 sunRIZE study of ersodetug in congenital (cHI).

In addition to the previously reported topline results, the oral presentation also included results from pre-specified and post-hoc sunRIZE analyses, which we believe reiterate evidence of target engagement and the potential therapeutic benefit of ersodetug.

This is an important step toward advancing care and improving outcomes for the community. We're grateful to the clinical partners, patients, and families who make this important work possible.

Learn more: https://bit.ly/4cIntBw

Address

275 Shoreline Drive, Ste. 500
Redwood City, CA
94065

Telephone

+16502064507

Website

http://www.rezolutebio.com/

Alerts

Be the first to know and let us send you an email when Rezolute posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Rezolute:

Shortcuts

Want your business to be the top-listed Engineering Company in Redwood City?